The JPG is the voice of the Japanese life sciences industry in the UK, made up of 12 companies whose global HQs are based in Japan.

• Our members employ approximately 3,000 people across UK affiliates, European HQs and research and manufacturing
• JPG companies bring the best of Japanese innovation to UK patients
• We also invest in UK life sciences, being involved in various research partnerships in the UK, actively scouting for scientific opportunities and have significant investments in UK biotech and clinical trials
• In 2023/4 JPG members
  • Made 31 significant investments in UK biotech, with one major acquisition
  • Invested in 60 academic programmes across multiple universities in England, Scotland and Wales
  • Participated in more than 10 cross sector research collaborations
  • Undertaking approx. 30 early-stage trials and over 50 phase III studies
  • Supported over 10 charitable research foundations
• Our ambition is to partner with Government to increase Japanese investment in the UK ecosystem and an important part of this is our roundtable event bringing together Government, leaders in UK Life Sciences and the global heads of R&D in our member companies
• In addition to delivering a successful event, our current priorities are implementation of the Independent Review of Clinical trials, evolution of MHRA as a sovereign regulator and implementation of the 2024 VPAG, particularly the Investment Programme.

In October 2024 we welcomed members of the Japanese Pharmaceutical Manufacturers Association to the UK, celebrating the contribution of the Japanese Life Sciences to the UK.